**A Multi-scale Systems Pharmacology Approach to TB Treatment (**1U01HL131072)

Jennifer J. Linderman1**\***, Elsje Pienaar1,2, Joseph Cicchese1, JoAnne Flynn3, Veronique Dartois4, Denise E. Kirschner2

1Department of Chemical Engineering, University of Michigan, Ann Arbor, MI

2Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI

3Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA

4 Public Health Research Institute Center, New Jersey Medical School, Rutgers, NJ

**ABSTRACT:** Tuberculosis (TB) is a pulmonary disease resulting from infection with *Mycobacterium tuberculosis* (Mtb). TB is treatable but requires multiple antibiotics taken for >6 months, and the emergence of drug-resistant Mtb has strained our current small arsenal of effective TB drugs. Lung granulomas that form in response to TB pose a two-fold challenge to TB treatment: granulomas present a physical barrier to antibiotic penetration, and bacterial subpopulations with diminished antibiotic susceptibility emerge within granulomas. These difficulties contribute to the challenge of devising new and more effective treatment strategies for TB: getting the right drugs at the right concentration to the right location to kill the appropriate bacterial subpopulation.Processes that participate in these dynamics act across scales ranging from *molecular* (e.g. drug diffusion), *cellular* (e.g. macrophage activation), *tissue* (e.g. granuloma formation), *organs* (e.g. blood delivery of antibiotics) up to the *entire host*. We use a multi-scale systems pharmacology approach with computational modeling to track drug distributions in granulomas and development of resistance. We partner modeling with state-of-the-art experimental methods for imaging drug distribution within granulomas from humans, non-human primates (NHP) and rabbits. In this new work, we propose to: (1) Determine the spatial and temporal distributions of TB antibiotics within granulomas, and predict the development of resistance; (2) Identify optimal antibiotic treatment regimens for TB using search algorithms to narrow the combinatorial design space of antibiotics (e.g. drug classes, dose, frequency); (3) Perform virtual clinical trials at a population level to test treatment regimens we identify, and test the optimal regimen in the NHP system against a standard regimen. We highlight approaches and results that we obtained during the first few months of funding.

**Papers published on this work:**

1. Pienaar E, Dartois V, Linderman JJ, Kirschner DE. *In silico* evaluation and exploration of antibiotic tuberculosis treatment regimens. BMC Systems Biology. 2015;9:79.

2. Pienaar E, Cilfone NA, Lin PL, Dartois V, Mattila JT, Butler JR, Flynn JL, Kirschner DE, Linderman JJ. A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment. J Theor Biol. 2015;367:166-179.

3. Cilfone N, Pienaar E, Thurber G, Kirschner D, Linderman JJ*.* A systems pharmacology approach towards the design of inhaled formulations of rifampicin and isoniazid for treatment of tuberculosis. CPT Pharmacometrics Syst. Pharmacol. (2015) 4, e22, DOI: [10.1002/psp4.22](http://dx.doi.org/10.1002/psp4.22" \t "_blank),

4. Linderman JJ, Cilfone NA, Pienaar E, Gong C, Kirschner DE. 2015. A Multi-Scale Approach to Designing Therapeutics for Tuberculosis. Integrative Biology 7 (5): 591–609.

5. Linderman JJ, Kirschner DE, [In silico models of M. tuberculosis infection provide a route to new therapies](http://authors.elsevier.com/a/1SDZL6BoAbcYJp" \t "_55), Drug Discovery Today: Disease Models, Volume 15, Spring 2015, Pages 37-41, DOI: [10.1016/j.ddmod.2014.02.006](http://dx.doi.org/10.1016/j.ddmod.2014.02.006" \t "_blank)

**\*Presenter**